Navigation Links
SEC in Medical Technology

Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA

...by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the sec and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in san...

Covance Receives Highest Level of Phase I Accreditation

...ations in more than 25 countries, and more than 10,000 employees worldwide. Information on Covance's products and services, recent press releases, and sec filings can be obtained through its website at www.covance.com . Statements contained in this press release, which are not historical facts,...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

...arly trials may not be repeated in later trials, and Rigel's need for additional capital, as well as other risks detailed from time to time in Rigel's sec reports, including its Form 10-Q for the quarter ended March 31, 2009. Rigel does not undertake any obligation to update forward-looking statements. ...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

...markets the Companies serve. Actual results may differ materially from these forward-looking statements due to a number of factors. See the Companies' sec filings, and in particular, the risk factors described in their Annual Reports on Form 10-K and their most recent report on Form 10-Q. The Companies d...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

...on Amylin, Lilly and/or Alkermes. These and additional risks and uncertainties are described more fully in Amylin's, Lilly's and Alkermes' most recent sec filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin, Lilly and Alkermes undertake no duty to update these f...

CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series

...f the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's sec filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to public...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

...ise in the clinical testing and approval process and Rigel's need for additional capital, as well as other risks detailed from time to time in Rigel's sec reports, including its Form 10-Q for the quarter ended March 31, 2009. Rigel does not undertake any obligation to update forward-looking statements. ...

5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH

...essful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the sec and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in...

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech

...ty of Sangamo and its collaborators to develop commercially viable products and technological developments by our competitors. See the company's sec filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. ...

Sanofi-aventis Stands Behind the Safety of Lantus(R)

...essful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the sec and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in...

Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies

...rations in more than 25 countries, and more than 9,800 employees worldwide. Information on Covance's products and services, recent press releases, and sec filings can be obtained through its website at www.covance.com . Statements contained in this press release, which are not historical facts, a...

Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug

...ional uncertainties and risks are described in Cordex's most recently filed sec documents, such as its most recent annual report on Form 10-K, all quarterl... of the last Form 10-KSB. Copies of these filings are available through the sec website at http://www.sec.gov . All forward-looking statements are bas...

New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring

...r ended April 4, 2009, filed with the Securities and Exchange Commission (" sec ") on May 6, 2009, which may be obtained for free at the SEC's website at ...r ended April 4, 2009, filed with the Securities and Exchange Commission (" sec ") on May 6, 2009, whether as a result of new information, future events or...

Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009

...ommercialization of pharmaceutical products. These and additional risks and uncertainties are described more fully in Amylin's and Lilly's most recent sec filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin and Lilly undertake no duty to update these forward-loo...

Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery

...rs" section of our Quarterly Report on Form 10-Q for the fiscal quarter year ended April 4, 2009, filed with the Securities and Exchange Commission (" sec ") on May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our fo...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...se factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the sec on May 11, 2009, as well as other filings by the company with the SEC. ...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...se factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the sec on May 11, 2009, as well as other filings by the company with the SEC. ...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

...on Amylin, Lilly and/or Alkermes. These and additional risks and uncertainties are described more fully in Amylin's, Lilly's and Alkermes' most recent sec filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin, Lilly and Alkermes undertake no duty to update these f...

Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients

...ons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the sec or posts certain other information to the website. Poster #466-P; Session PO01, June 6, 11:30 A.M. - 1:30 P.M. Poster #479-P; Session PO02, Jun...

AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA

...ons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the sec or posts certain other information to the website. CONTACT: Alanna Jamieson, MCS Healthcare Public Relations, alannaj@mcspr.com " target="_new...

CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

...f the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's sec filings, including but not limited to its report on Form 10-K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicl...

Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting

...cussed in the "Risk Factors" section of the company's Annual Report on Form 10-KSB for the year ended December 31, 2008 and the company's other recent sec filings. The company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this pr...

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

...by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the sec and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in san...

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

...ble to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's sec reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the ...

Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

...s, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent sec filings. ...

Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials

...ore fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 as filed with the sec on May 8, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this pr...

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction

...pany has filed with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the sec are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any...

Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

... on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended March 31, 2009, which was filed with the sec on May 11, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this releas...

PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide

...ore fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 as filed with the sec on May 8, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this pr...

Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting

...tion from other technologies. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's sec filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company und...

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS

...ng a metered dose Inhaler (MDI) via a holding chamber. The study compared various lung function parameters, such as forced expiratory volume in 1 sec (FEV1), forced vital capacity (FVC), mean expiratory flow (MEF 50% pred), inflammatory markers, such as serum percent Eosinophils and expired nitric o...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

...ut are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the sec on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive...

New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease

...rs" section of our Quarterly Report on Form 10-Q for the fiscal quarter year ended April 4, 2009, filed with the Securities and Exchange Commission (" sec ") on May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our fo...

Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business

...usiness or stock price which could cause actual results to materially differ from those in forward-looking statements is contained in Encorium Group's sec filings, including its Annual Report on Form 10-K for the year ended December 31, 2008 and other periodic reports under the Securities Exchange Act of...

PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009

...sk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2008, and our other sec reports. PLC Systems, PLC Medical Systems, PLC and CO2 Heart Laser, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc. ...

Food and Drug Administration Accepts Isolagen's Biologics License Application for Full Review

...e other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, as well as other public filings with the sec since such date. ...

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

...uture one to two fiscal quarters, and to provide, update or reconfirm its guidance only by issuing a press release or filing updated guidance with the sec in a publicly accessible document. Clinical guidance is as of May 7, 2009 and financial guidance relating to the Company's current cash, cash equival...

Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update

...Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended March 31, 2009, which will be filed with the sec on or about May 11, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of th...

Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients

...ble to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's sec reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for th...

Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs

... fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2008 as filed with the sec on February 9, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in th...
Other Tags
(Date:7/11/2014)... of Entiat on Tuesday, July 8, 2014. Despite the ... over 1,000 acres by evening. Three outbuildings were damaged. ... the Washington Department of Natural Resources. The fire ... fire control strategies and tactics. Other cooperators include the ... Resources, (WA DNR), Bureau of Land Management, Chelan County ...
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
(Date:7/11/2014)... Researchers from Ume University, Sweden, have explored two ... the reaction sequence leading to the formation of ... been published in the scientific journal Nature ... improving present day synthetic catalysts for water oxidation, ... devices for the direct storage of solar energy ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
(Date:7/13/2014)... (PRWEB) July 13, 2014 The ... Copper, Molybdenum, Iron), Form (Chelated & Non Chelated), ... Geography - Global Trends and Forecast to 2018” ... with an analysis and forecasting of the global ... identifies the driving and restraining factors for the ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study ... Scanning; 3D rendering; Layout and Animation; Image Reconstruction]: ... 2018)”, which analyzes and studies the major market ... Europe, Eastern Europe, Middle East and Africa, Asia-Pacific ... competitive landscape of the 3D imaging market, providing ...
(Date:7/13/2014)... 2014 Athletes with a certain genetic ... concussions, according to research presented today at the American ... Meeting. The research marks the first of its kind ... known physical events that occur after a head injury. ... allele in the (GT)n genotype were four times more ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular suppliers of ... its new range of elegant Quinceanera dresses . ... discounted prices. Worldwide clients can enjoy this special offer ... online shop, there are plenty of beautiful dresses for ... materials. MyDressCity.com’s hot items are prom gowns, bridesmaid gowns, ...
(Date:7/13/2014)... decreased ability to identify odors might indicate the ... examinations of the eye could indicate the build-up ... the brain, according to the results of four ... International Conference 2014 (AAIC 2014) in Copenhagen. , ... to identify odors was significantly associated with loss ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
Other Contents